We have located links that may give you full text access.
JOURNAL ARTICLE
REVIEW
Proton pump inhibitors in acute healing and maintenance of erosive or worse esophagitis: a systematic overview.
Canadian Journal of Gastroenterology 1997 September
The aim of this paper is to present a systematic overview of the efficacy of the proton pump inhibitors (PPI), omeprazole and the newer lansoprazole, in the healing and maintenance of erosive or worse (grade II to IV) esophagitis. At the time of the 1996 gastroesophageal reflux disease (GERD) consensus meeting, a third PPI, pantoprazole, was not yet available in Canada and was, therefore, not discussed. The present review is therefore restricted to patients with more severe disease than that of the average patient who presents to the family physician with symptoms of mild GERD. In these patients with endoscopic evidence of damaged esophageal mucosa, both proton pump inhibitors were highly effective and safe in acute healing of erosive esophagitis and were significantly better than H2 receptor antagonists, healing faster and much more completely, with shorter durations of treatment. Suggested initial doses were omeprazole 20 mg once daily and lansoprazole 30 mg once daily, which were consistent with the manufacturer's recommendations. Once patients with this degree of esophagitis have their mucosal lesions healed, they almost inevitably have recurrence of esophagitis (80% at one year) unless some form of maintenance therapy is continued. Unfortunately, for these patients with healed erosive or ulcerative esophagitis, H2 receptor antagonists appear to be no better than placebo, and a PPI is the only class of drug able to minimize relapse significantly.
Full text links
Related Resources
Trending Papers
Heart failure with preserved ejection fraction: diagnosis, risk assessment, and treatment.Clinical Research in Cardiology : Official Journal of the German Cardiac Society 2024 April 12
Proximal versus distal diuretics in congestive heart failure.Nephrology, Dialysis, Transplantation 2024 Februrary 30
Efficacy and safety of pharmacotherapy in chronic insomnia: A review of clinical guidelines and case reports.Mental Health Clinician 2023 October
World Health Organization and International Consensus Classification of eosinophilic disorders: 2024 update on diagnosis, risk stratification, and management.American Journal of Hematology 2024 March 30
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app
All material on this website is protected by copyright, Copyright © 1994-2024 by WebMD LLC.
This website also contains material copyrighted by 3rd parties.
By using this service, you agree to our terms of use and privacy policy.
Your Privacy Choices
You can now claim free CME credits for this literature searchClaim now
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app